Novartis Investor Presentation

New Novartis: Our strategy 2. Launch excellence Existing in-market brands with multi-bn potential are the foundations Our focus Our priorities Improved financials > Launch excellence High-value innovation Operational excellence Strengthen foundations Conclusion Abbreviations Q2 2022 sales annualized Q2 growth in cc 18 Cosentyx® USD 5.1 bn +12% CEZ K KK KL Entresto Ⓡ zolgensma® KISQALIⓇ Kesimpta® LEQVIO® USD 4.5 bn USD 1.5 bn USD 1.2 bn USD 1.0 bn USD 0.1 bn +33% +26% +43% +270% nm Peak sales USD >7bn US LOE 2029+ Peak sales USD >5bn US LOE 2025+ Peak sales multi-bn¹ US LOE 2031+ Peak sales multi-bn US LOE 2031+ Peak sales multi-bn US LOE 2031+ nm - not meaningful. LOE - Loss of exclusivity. All growth rates in constant currencies (cc). US LoEs are estimated based on relevant patents; further extensions possible. 1. Including ZolgensmaⓇ IT. Novartis Investor Presentation | September 22, 2022 Peak sales multi-bn US LOE 2036+ 1 | NOVARTIS | Reimagining Medicine

View entire presentation